[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345010-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345010-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","reply-fusion-dnajb1prkaca-in-non-fibrolamellar-cancer-cases-absence-of-the-dnajb1prkaca-fusion-in-hepatoblastoma","Reply - Fusion DNAJB1::PRKACA in Non-Fibrolamellar Cancer Cases - Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma","","Reply to Arif et al. and comment on Fleifil et al. addressing DNAJB1::PRKACA in pediatric liver cancers. The authors report assessing DNAJB1::PRKACA (DNAJB1-PKAc/J-PKAc) in Bio Bank samples from hepatoblastoma and hepatocellular malignant neoplasm, not otherwise specified collected at Cincinnati Children’s Hospital Medical Center over five years. Their results show ~70% fusion detection with variable expression, while their response explains how sensitivity, patient age, and assay optimization may account for differences with the commentary’s non-detection findings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/reply-fusion-dnajb1prkaca-in-non-fibrolamellar-cancer-cases-absence-of-the-dnajb1prkaca-fusion-in-hepatoblastoma/345010/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/reply-fusion-dnajb1prkaca-in-non-fibrolamellar-cancer-cases-absence-of-the-dnajb1prkaca-fusion-in-hepatoblastoma/345010.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What fusion is discussed, and in which cancer context is it evaluated?","Question",{"text":63,"@type":64},"The discussion centers on the DNAJB1::PRKACA (DNAJB1-PKAc/J-PKAc) fusion and its expression in hepatoblastoma and hepatocellular malignant neoplasm, not otherwise specified, which are non-fibrolamellar contexts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the authors find about DNAJB1::PRKACA detection in their cohorts?",{"text":68,"@type":64},"They detected DNAJB1::PRKACA in approximately 70% of HBL/HCN-NOS patients, with about 30% showing no detectable expression. They also identified two fusion-positive expression groups: low fusion kinase levels versus levels resembling fibrolamellar carcinoma.",{"name":70,"@type":61,"acceptedAnswer":71},"Why might the results differ from those reported in Arif et al.’s commentary?",{"text":72,"@type":64},"The authors suggest discrepancies could stem from differences in assay sensitivity for low concentrations, the optimization conditions for detecting strong fusion levels, and patient age at the time of DNAJB1::PRKACA analysis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345010,1791002802,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":123,"preview_page_count":33,"preview_urls":144},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Reply  \nFusion DNAJB1::PRKACA in Non-Fibrolamellar Cancer Cases. Reply to Arif et al. Global Re-Analysis Confirms Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma. Comment on“Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83”  \nYasmeen Fleifil 1, Ruhi Gulati 1, Katherine Jennings 2, Alexander Miethke 3, Alexander Bondoc 1,4, Gregory Tiao 1,4, Rebekah Karns 3, Lubov Timchenko 2 and Nikolai Timchenko 1,4, *  \nAcademic Editor: Samuel C. Mok  \nReceived: 20 January 2026  \nRevised: 6 February 2026  \nAccepted: 26 February 2026  \nPublished: 12 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of General and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA; yasmeen.fleifil@cchmc.org (Y.F.); ruhi.gulati@cchmc.org (R.G.); [alex.bondoc@cchmc.org](alex.bondoc@cchmc.org) (A.B.); [greg.tiao@cchmc.org](greg.tiao@cchmc.org) (G.T.)  \n2 Department of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA; [katherine.jennings@cchmc.org](katherine.jennings@cchmc.org) (K.J.); [lubov.timchenko@cchmc.org](lubov.timchenko@cchmc.org) (L.T.)  \n3 Department of Gastroenterology, Hepatology & Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA; [alexander.miethke@cchmc.org](alexander.miethke@cchmc.org) (A.M.); [rebekah.karns@cchmc.org](rebekah.karns@cchmc.org) (R.K.)  \n4 Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA  \n* [Correspondence: nikolai.timchenko@cchmc.org](Correspondence: nikolai.timchenko@cchmc.org)  \nAbstract  \nArif and colleagues commented on our paper Fleifil et al.“DNAJB1-PKAc is expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways”published in Cancers in 2024 . In our paper, we examined expression of DNAJB1::PRKACA (DNAJB1-PKAc or J-PKAc) in the Bio Bank of HBL (Hepatoblastoma) and HCN-NOS (Hepatocellular Malignant Neoplasm, Not Otherwise Specified) tissue samples collected at CCHMC during the last five years. Our data demonstrated that DNAJB1::PRKACA was detected in approximately 70% of HBL/HCN-NOS patients, with varying expression levels. In the commentary, the authors reviewed their earlier data and found no evidence of the fusion DNAJB1-PKAc expression within their cohorts of HBL specimens. Based on these data, the authors stated that “. . .DNAJB1::PRKACA remains specific to fibrolamellar carcinoma among liver tumors and caution against its use as a diagnostic marker for hepatoblastoma without rigorous validation in external cohorts.” After reviewing the commentary, we are offering a response outlined below.  \nKeywords: FLC; fusion DNAJB1::PRKACA; pediatric liver cancers  \nKey findings and interpretations from our Cancers paper.  \nIn our study, we detected expression of DNAJB1::PRKACA in approximately 70% of children in our HBL/HCN-NOS and biliary atresia cohorts. Approximately 30% of examined patients did not show expression of DNAJB1::PRKACA. Within our patients, we identified two groups of fusion-positive pediatric HBL/HCN-NOS; one group had low levels of the fusion kinase compared to FLC, whereas the second group expressed DNAJB1::PRKACA at levels like FLC (Figure 1B,[Ref \\#1]) [1] . Thus, while about 70% of  \nour non-FLC patients expressed DNAJB1::PRKACA, only some reached expression levels similar to FLC patients. We suggest that the detection of DNAJB1::PRKACA in non-FLC patients requires highly sensitive assays and maybe missed if conditions are only optimized for strong fusion kinase levels, as seen in FLC. This may explain the differences between our findings and those of Arif et al. [2] . Arif’s commentary examined DNAJB1::PRKACA levels, comparing the genera","cbCaia1cNcoxkqJ2","https://ap.wps.com/l/cbCaia1cNcoxkqJ2","pdf",182690,"English","# Abstract\n# Key findings and interpretations\n## Fusion detection rates and expression groups\n## Assay sensitivity and possible reasons for discrepancies\n## Transcriptomic and pathway evidence","[{\"question\":\"What fusion is discussed, and in which cancer context is it evaluated?\",\"answer\":\"The discussion centers on the DNAJB1::PRKACA (DNAJB1-PKAc/J-PKAc) fusion and its expression in hepatoblastoma and hepatocellular malignant neoplasm, not otherwise specified, which are non-fibrolamellar contexts.\"},{\"question\":\"What did the authors find about DNAJB1::PRKACA detection in their cohorts?\",\"answer\":\"They detected DNAJB1::PRKACA in approximately 70% of HBL/HCN-NOS patients, with about 30% showing no detectable expression. They also identified two fusion-positive expression groups: low fusion kinase levels versus levels resembling fibrolamellar carcinoma.\"},{\"question\":\"Why might the results differ from those reported in Arif et al.’s commentary?\",\"answer\":\"The authors suggest discrepancies could stem from differences in assay sensitivity for low concentrations, the optimization conditions for detecting strong fusion levels, and patient age at the time of DNAJB1::PRKACA analysis.\"}]","Reply - Fusion DNAJB1::PRKACA in Non-Fibrolamellar Cancer Cases - Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma | PDF",1790056198,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c20bfeb476fd5b1ff40b3eee6216ead9.webp",983,1390,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbc77f83b27d5657fdf25f4144065a66.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec2e7d4a920f37c6e1c9c8d6a554f82a.webp",981,1387,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b34d98e015bd4bf203831a8742a2e9ef.webp",980,1385]